‘Mass Spectrometry Market Worth Over $3.8 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography indicates that the global mass spectrometry market will see over $3.8bn in revenue in 2017.

The lead analyst of the report said:

“The mass spectrometry market is expected to experience considerable growth over the forecast period. The main drivers for the growth include the applications of the mass spectrometry in wide range of areas, technological advancements and adoption/acceptability of new technology by the government to address the healthcare challenges. The increasing disease burden and identification of antibacterial resistant strains is leading to therapeutical advancements, drug discovery and increase research and development activities to address this situation. The high-speed, accurate, sample analysis of simple to complex molecules/products by the mass spectrometry is leading to its increased demand in the areas such as clinical research, proteomic, metabolomics, and forensics including many others.”
The 183-page report contains 111 tables, charts and graphs that add visual analysis in order to explain developing trends within the mass spectrometry market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading mass spectrometry submarkets, segmented by technology, with forecasts for single and hybrid mass spectrometry. The market is also segmented by product, and includes forecasts for Ion Trap, Quadrupole, TOF, Triple Quadrupole, Quadrupole-TOF and Fourier Transform Mass Spectrometry. The report also includes forecasts for the applications of mass spectrometry, including academic, biotech, agriculture, contract research, hospital, environmental and material usage.

The 183-page report offers market forecasts and analysis for 4 regional and 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the field in mass spectrometry technology.

The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography report will be of value to anyone who wants to better understand the mass spectrometry market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the mass spectrometry industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever